Bayer Pharma AG

VTE Risk Assessment Guide

Select VTE risk factors

Select the relevant risk factors to create an individual’s specific risk profile for developing venous thromboembolism (VTE). Each of the factors is rated as a major or an intermediate risk based on expert consensus and epidemiological data.

The risk assessment guide is based on scientific evidence. It is not intended as medical advice nor to substitute for a physician's consultation.

Risk Factors
Intermediate Major

The aetiology of VTE is often multifactorial. The presence of multiple risk factors increases the probability of developing VTE. Clinicians should consider an individual's risk profile in its entirely when contemplating thromboprophylactic therapy.

Geerts WH, Pineo GF, Heit JA, et al. Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004;126(3 suppl): 338S-400S.

Kucher N, Koo S, Quiroz R, Cooper JM, Paterno MD, Soukonnikov B, Goldhaber SZ. Electronic alerts to prevent venous thromboembolism among hospitalized patients. N Engl J Med. 2005;352(10):969-977.

Alikhan R, Cohen AT, Combe S, et al; MEDENOX Study. Risk factors for venous thromboembolism in hospitalized patients with acute medical illness: analysis of the MEDENOX Study.Arch Intern Med. 2004;164(9):963-968.

Guidelines for VTE prevention (German AWMF). Available at

Selected Articles

People who read this article, also read these articles: